Document is current
Any future updates will be listed below
-
Authors
Lehto, Annaliis https://orcid.org/0000-0003-3459-8226
Schumacher, Julia https://orcid.org/0000-0001-7323-4789
Kasper, Elisabeth
Teipel, Stefan https://orcid.org/0000-0002-3586-3194
Hermann, Andreas https://orcid.org/0000-0002-7364-7791
Kurth, Jens https://orcid.org/0000-0001-6864-4513
Krause, Bernd Joachim
Prudlo, Johannes https://orcid.org/0000-0002-7932-5929
-
Funding
Funding for this research was provided by:
André Greipel and “Fight ALS” initiative
Boris Canessa ALS Foundation
Bundesministerium für Bildung und Forschung/Verein Deutscher Ingenieure (13GW0482D)
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft
- License Information
-
More Information
Article History
Received: 9 February 2024
Revised: 8 April 2024
Accepted: 15 April 2024
First Online: 11 June 2024
Declarations
:
: S.T. served on advisory boards of Lilly, Eisai, and Biogen, and is member of the independent data safety and monitoring board of the ENVISION study (Biogen).
: The study was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Patients gave their written informed consent, and the local ethics committee at the Rostock University Medical Centre approved the study (2022–0081).
